Prevalence of renal and hepatobiliary disease, laboratory abnormalities, and potentially toxic medication exposures among persons with COPD
Douglas W Mapel,1 Jenõ P Marton21Lovelace Clinic Foundation, Albuquerque, New Mexico, NM, USA; 2Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USABackground: The purpose of this study was to describe the prevalence of renal and hepatic disease, related laboratory ab...
Main Authors: | Mapel DW, Marton JP |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-03-01
|
Series: | International Journal of COPD |
Online Access: | http://www.dovepress.com/prevalence-of-renal-and-hepatobiliary-disease-laboratory-abnormalities-a12488 |
Similar Items
-
Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients
by: Make B, et al.
Published: (2012-01-01) -
Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP)
by: Cheryl Enger, et al.
Published: (2011-04-01) -
Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims
by: Mapel DW, et al.
Published: (2011-11-01) -
Dose and batch-dependent hepatobiliary toxicity of 10 nm silver nanoparticles
by: Marcella De Maglie, et al.
Published: (2015-07-01) -
Prevalence of chronic renal failure in COPD patients
by: Ibrahim I. Elmahallawy, et al.
Published: (2013-04-01)